Video
Top 10 Most HARMFUL Foods Thought As HEALTHYDiabetes and cardiovascular health -
It is unclear what causes type 1 diabetes. What is known is that your immune system attacks cells in your pancreas. There is thought to be a link between diabetes, genetics and environmental factors. There is a strong link between being overweight and type 2 diabetes.
Genetic and environmental factors may also play a role. Having gestational diabetes increases the risk of the mother and child developing diabetes later in life.
Having a family member with diabetes puts you at risk for both types. If you have diabetes, encourage your family members to get tested. The definite risk factors for type 1 diabetes are not known. But having a family member with type 1 diabetes increases your risk for developing it.
There are several risk factors for type 2 diabetes. Many of these are also risk factors for heart disease, stroke and other chronic conditions.
They include:. Symptoms for type 1 diabetes usually develop suddenly and quickly. Type 2 symptoms develop more slowly. If you have type 2 diabetes, you may not have any symptoms at all. Your doctor will diagnose diabetes after reviewing your symptoms, taking a medical history and giving you a complete physical exam.
Tests will be done to measure glucose levels in your blood. The A1C test measures glucose and reflects your average blood sugar levels over the past months.
If the A1C test is not available or you are unable to take this test for any reason like pregnancy , you may be asked to take one of the following tests:. Managing your diabetes is important to prevent heart disease and stroke.
Treatment for diabetes may include medication and lifestyle changes. You and your doctor will discuss the treatment options and decide which is best for you. Insulin Insulin therapy is required for the treatment of type 1 diabetes. Your doctor will help you to understand the dosage, timing and number of injections you might need.
People living with type 2 diabetes may also need insulin. The key to managing type 2 diabetes is monitoring and maintaining your blood sugar levels in the target range set by you and your healthcare provider.
Healthy lifestyle choices can help bring your blood sugar level back to normal or keep it from rising. The good news is that the lifestyle changes you need to make are the same choices that will help you to lower your risk of heart disease, stroke and other medical conditions.
Find more information on how to get healthy. Controlling blood sugar with medication There are several oral medications to treat type 2 diabetes that work in different ways to control blood sugar by increasing insulin production, making you more sensitive to insulin or slowing digestion.
You might also need medications to control your cholesterol and high blood pressure. Learn more about medications that can protect you from heart disease and stroke.
Here are the ABCDESSS of living with diabetes. Follow these basic steps to protect your health:. A: A1C. Monitor and control your blood sugar levels. B: Blood pressure. Know your blood pressure and take steps to keep it in a healthy range.
C: Cholesterol. Make sure your LDL cholesterol levels are low. D: Drugs to decrease heart disease risk. This might include blood pressure pills, cholesterol-lowering pills and others. E: Exercise and healthy eating. S: Self-management support. Set goals to reach and maintain a healthy lifestyle and understand what stands in your way.
S: Screening or monitoring for complications. Thus, the NEFAs release may be influenced by the presence in different tissues [ 17 ]. Fat of intra-abdominal is more crucial in the resistance of insulin as it is more lipolytic and does not easily react to insulin activity of antilipolytic [ 19 , 20 ].
CVD is also interlinked with diabetes and obesity due to the association of inflammation low grade as shown in Fig. The overexpression of cytokines like IL-6, IL-1, leptin, PAI-1, resistin MCP-1, angiotensin, and TNF fibrinogen causes inflammation to increase and lipid to accumulate that in turn have a disastrous impact on vessels of blood and can ultimately cause endothelial dysfunction, cardiomyopathy, and myocardial infarction [ 12 , 13 , 14 , 15 , 16 , 21 ].
These cytokines overexpression links the association of resistance of insulin and DM. Relationships between high-risk obesity, intermediate cardiometabolic risk factors, and cardiovascular outcomes obesity phenotypes, diabetes, and cardiovascular diseases.
Hypertension is very common among diabetics and one of the highly prevalent diseases around the world. Sixty percent of diabetes 2 patients have hypertension in adjunct [ 22 , 23 ]. The two conditions when coexists increase the chances of both complications, i.
Complications of macrovascular include infarction of myocardial and stroke whereas complication of microvascular includes retinopathy and nephropathy [ 24 ]. The onset of hypertension in diabetics relies on diabetes type. In diabetes type 1 , hypertension onset appears after years of diagnosis and majorly have diabetic nephropathy [ 23 ].
Hypertension can be present before the glucose level increases in the body in diabetes 2 patients [ 25 ]. The development of diabetic nephropathy is closely related to patients with diabetes and hypertension [ 26 ].
Hyperglycemia stimulates the renal cells and as a result cytokines, humoral mediators, and growth factors are produced. This production causes an alteration in the structure of glomeruli of a diabetic patient, an increase in the matrix of extracellular collagen deposition, and a rise in glomerular basement membrane permeability [ 27 ].
The structural changes result in microalbuminuria and chronic generation of RAAS renin-angiotensin system which progresses into hypertension [ 28 ]. Dm is involved with various mechanisms pathophysiologically as shown in Fig. Diabetes and hypertension have interlinked pathways like the stress of oxidation, renin-angiotensin-aldosterone system RAAS , resistance of insulin, SNS sympathetic nervous system, PPARs, and adipokines.
These pathways are interconnected and interact with each other and may even result in a vicious cycle [ 29 , 30 ]. The development of proteinuria in diabetic patients leads to hyperlipidemia which increases the chances of CVD in these patients. Summary of pathophysiologic mechanisms in the development of hypertension in diabetes mellitus VSMC—vascular smooth muscle cell.
Diabetic patients are at an increased prevalence of dyslipidemia development [ 31 ]. The proposed underlying pattern observed in the development of dyslipidemia in diabetic patients is an increased level of triglycerides, LDL low-density lipoprotein , and reduced level of HDL-C high-density lipoprotein cholesterol [ 32 ].
One of the prominent features of dyslipidemia in diabetes is an elevated number of LDL particles from either LDL-P or ApoB. There is also an associated high risk of nephropathy as LDL particles tend to be more atherogenic [ 33 ].
Lipid abnormalities in diabetic patients are shown in Table 2. The main underlying mechanism for the development of dyslipidemia in diabetic patients is insulin resistance as shown in Fig. Adipose tissue release of free fatty acids increases in the case of peripheral insulin resistance, which are further entrapped by the liver, in turn, leads to the elevated synthesis of TG triglycerides by the hepatic cells.
There is an elevation in ApoB secretion and synthesis of triglyceride-rich VLDL very low-density lipoprotein due to the hepatic stimulation caused by triglyceride synthesis [ 39 ]. The highly loaded VLDL with triglycerides enriches HDL and LDL and makes them richer in cholesterol through the work of cholesterol ester transfer protein [ 40 ].
The triglyceride-rich LDL molecules aid in the synthesis of small dense LDL as it gets hydrolyzed by lipoprotein lipase or hepatic lipase. This underlying pathophysiology of dyslipidemia increases the CVD prevalence in patients of diabetes. Modern therapy of diabetic patients necessitates lipids to be treated to decrease the risk of cardiovascular diseases.
The development of cardiomyopathy is a direct consequence of DM. The pathophysiological pathways of cardiomyopathy of diabetes are shown in Fig. The diabetic cardiomyopathy shows heart changes functionally and the left ventricle changes structurally [ 41 ].
The diabetic patient shows to have increased left ventricle mass as compared to non-diabetics [ 42 , 43 ]. It may be proposed that the increased cardiac mass in diabetics is due to the increased release of cytokines having hypertrophic effects on cardiac cells like resistin and leptin from the adipocytes [ 44 , 45 ].
Patients with diabetes mellitus are also found to have slightly decreased diastolic function in comparison to non-diabetic [ 46 , 47 , 48 ]. Mechanisms contributing to diabetic dysfunction of the cardiac system are shown in Table 3.
One proposed mechanism for the same could be the increased triglyceride content in the cardiomyocytes due to the elevated synthesis of triglycerides in diabetics [ 49 ].
As a response to triglyceride accumulation in the myocardium, there is a chance of lipotoxicity and the calcium hemostasis also is altered. Both of these factors harm the diastolic function [ 50 , 51 , 52 ]. Subtle alterations have also been found in systolic functioning in diabetic patients using Doppler strain analysis of systolic velocity and tissue Doppler imaging [ 53 , 54 , 55 , 56 , 57 ].
The systolic dysfunction can be due to the impaired contractile reserve and impaired sympathetic innervation of the myocardium [ 58 ]. Interstitial fibrosis accompanying elevated collagen deposition is also seen in diabetic patients and has a negative impact on cardiac function [ 59 ].
The mechanisms following the diminished systolic and diastolic functions of the heart also increase the risk of having heart failures in diabetic patients [ 60 , 61 ]. Cardiovascular autonomic neuropathy CAN has been commonly noticed in diabetic patients [ 63 ]. It is one of the most overlooked complications in diabetic patients [ 64 , 65 , 66 ].
CAN involves the harm to fibers of the autonomic nerve. These autonomic fibers innervate the vessels of blood and the heart and the result is abnormalities in vascular dynamics and heart rate control [ 67 ].
The chances for a diabetic patient to have CAN persist from 2. An inter-link among inflammation, imbalance of autonomic, and CVD has been demonstrated in recent studies as increased inflammatory markers IL 1 and CRP are involved in dysregulation of ANS autonomic nervous system with elevated activity of the sympathetic system [ 69 , 70 ].
As the ANS is involved in activity modulation of the sinus node heart rate , end-diastolic and systolic volume, the resistance of systemic vascular, the dysregulation of the autonomic nervous system may result in left ventricular hypertrophy, arterial stiffness, and dysfunction of diastolic of the ventricle [ 71 ].
Clinical manifestations of CAN be named as follows: postural hypotension, abnormal coronary vasomotor regulation, tachycardia, the elevation of QT interval, increased danger of renal disease, exercise intolerance, death, and stroke [ 72 ].
CAN tends to be a robust presence of cardiovascular disease in both type 1 and type 2 diabetes. According to a study conducted, a complex interaction between duration of the disease, neuronal death relating to age, a diastolic and systolic pressure of blood, and control of glycemic results in diabetes-related CAN [ 66 ].
The main culprit is thought to be hyperglycemia that is involved in the stimulation of a cascade of multiple complex pathways and mechanisms which result in oxidative stress induction and production of toxic glycosylation substances that ultimately lead to neuronal abnormalities and death.
With age, the diabetics increase the chance of development of CVD and CAN [ 74 ]. Advanced glycation—a biochemical process that tends to accelerate in diabetes due to elevated oxidative stress and chronic hyperglycemia and is found to play a central role in diabetes.
Generation of the advanced glycated end products AGEs that are a heterogeneous group of chemical moieties takes place due to advanced glycation. This production of AGEs is a result of a non-enzymatic reaction involving vital intermediates such as methylglyoxal and a reaction with the glucose that interacts with lipids, nucleic acids, and proteins.
AGEs produce deleterious results in diabetic patients. AGEs can alter the structure and function of the vasculature as it promotes vascular stiffness by directly inducing the crosslinking of proteins such as collagen that are long lived.
AGEs also enhance the oxidative stress and release of key pro-sclerotic and proinflammatory cytokines by interacting with certain receptors such as RAGE receptor for AGE.
AGEs are heterogeneous complex moieties that are formed via a non-enzymatic reaction between glucose and other reducing sugars with amine residues on proteins, nucleic acids, or lipids. N carboxymethyl lysine and pentosidine are some of the prominent AGEs found in humans [ 75 , 76 ].
AGEs can be produced by exogenous sources also apart from endogenous production. Exogenous sources include tobacco smoke and diet [ 77 , 78 , 79 , 80 ]. Prolonged heating can accelerate the production of glycol oxidation and lipo-oxidation compounds. A major part of the ingested AGEs is absorbed with food.
AGEs often concentrate intracellularly as they are generated from dicarbonyl precursors derived from glucose [ 81 ].
The intracellular AGEs act as stimuli for intracellular signaling pathways activation as well as are also involved in the modification of intracellular protein function [ 82 ]. Accumulation of AGEs in organs damaged due to diabetes increases as a result of hyperglycemia. AGEs cause the crosslinking of intermolecular collagen that leads to diminished myocardial and arterial function.
It also increases vascular stiffness. All these phenomena can be used to partly explain the elevation in systolic hypertension and diastolic dysfunction noted in diabetic patients.
Some of the diabetic damaged sites of accumulation of AGEs are retina, kidney, and atherosclerosis plaques as shown in Table 4 [ 91 , 95 , 96 ]. The close association of DM and CVD and their factors give rise to the theory that both the conditions follow common genetic, epigenetic, and environmental factors.
Many SNP single nucleotide polymorphism are found to be associated with CVD and DM [ 97 ]. Recently, many non-coding RNA appeared as indispensable factors involved in the pathophysiology of both the conditions which underlie common epigenetic links between these two [ 99 , ].
CVD and DM are polygenic but Mendelian forms have been described for both the conditions where a single gene mutation initiates the disease [ , ].
However, all gene mutation does not predispose to both the disease. A recent study shows the protective role of Apo B gene mutation in DM which is the most commonly studied gene in familial hypercholesterolemia [ ].
Many loci are associated with both conditions. As of now, at least 83 loci are found to be associated with DM and more than 30 loci with CVD [ , ].
Some genes are shown in Tables 5 and 6 whose variants are involved in both the disease. Since CVD is perhaps the common cause of death and disease among diabetic patients, it is vital to have adequate therapy to minimize the chances for events of the cardiovascular system in patients with diabetes, especially with CHF chronic heart failure , stroke, and infarction of myocardia.
The enhanced chance of cardiovascular complications in patients is due to the factors like dysfunction of the autonomous system, dyslipidemia, hypertension, and obesity. Treatment aimed at improving these health risks can boost CV results, though this can be difficult to accomplish.
Investigation on how the CV risk level of people with diabetes is affected by these various risk factors may be vague and often conflicting. This section aims to include the current recommendations on several treatment strategies for the same.
Treatment approaches can be divided into lifestyle modifications and pharmacological interventions. Obesity is one of the major factors of risk which raises the prevalence of CVD-related mortality and morbidity in DM patients. So many clinical guidelines suggest reducing the weight of DM patients to reduce CVD risk profiles.
The syndrome of metabolic and resistance of insulin is found to play a prominent role in cardiovascular mortality and morbidity [ , ]. Type 2 DM along with visceral adiposity and an excess of ectopic fat clearly show high risks of cardiovascular morbidity and mortality [ ].
Individuals with high visceral adipose tissue—this is the condition where fat deposition occurs at lean tissues like the liver, the skeletal muscle, and the heart are at high risk. The simultaneous presence of obesity and DM should further increase the risk of cardiovascular outcomes [ ].
According to the trial of SCOUT, the modest loss of weight can enhance rates of mortality of CV in DM patients. Look AHEAD trial did not find any reduction in the chances of CV events like MI, stroke after weight loss in DM patients after 9.
Various pharmacological drugs are found to be effective in weight loss which reduces the CVD risk [ , , , , ]. Some drugs which are prescribed to control glucose level in DM patients are also effective in weight loss; GLP-1 glucagon-like peptide-1 receptor agonists and SGLT2 sodium-glucose co-transporter 2 inhibitors indicated efficacy towards weight loss in diabetes patients [ , ].
Surgical interventions are more effective for sustained weight loss than standard approaches [ , ]. Restrictive surgeries restrict the intake of food by reducing the size of the stomach and mal-absorption surgeries reduce the amount of absorption by bypassing the different parts of the small intestine.
Sleeve gastrectomy is the most famous restrictive type which reduces weight by reduced meal volume and reduced appetite. Both types of surgeries restrictive and bypass reduce visceral fat and reduce more subcutaneous fat levels [ , , ].
A retrospective study on 20, surgical and non-surgical treated patients demonstrated a reduction in incidences of coronary artery disease in patients who are treated with weight-loss surgeries [ ].
Similarly, another retrospective study on 12 patients with a heart attack and low ventricular ejection who underwent weight-loss surgery showed significant improvement in ventricular ejection following surgery [ ].
Treatment of obesity and maintenance of BMI could significantly improve the condition and could reduce the cardiovascular risk factors in DM patients.
The existence of hypertension in diabetic patients worsens the clinical outcomes of both macrovascular and microvascular diabetes. Their coexistence is the leading factor for atherosclerosis and linked complications [ ]. The pharmacological treatment for hypertension management is utilization of inhibitors of ACE angiotensin-converting enzyme , blockers of the receptor of the angiotensin receptor, diuretics, blockers of the channel of calcium which reduces blood pressure by blocking various receptors and channels that contribute to elevated blood pressure [ , , , ].
There have been many studies that evaluated high blood pressure BP role in DM patients on CV outcomes. The UKPDS 38 trial evaluated the significance of BP in DM patients on macrovascular and microvascular complications.
After 4. Also, the tight BP control group showed more chances of adverse events [ ]. Dyslipidemia is very prevalent in DM patients and an important risk factor for CVD [ ]. Weight loss improves blood pressure, reduces the level of triglycerides, and elevates HDL-C levels [ ].
Although the loss of weight has indicated to enhance factors of multiple risks like blood pressure and hemoglobin A1C, it did not show any significant improvement in events of cardiovascular in the Look AHEAD study [ ], indicating a necessity for pharmacotherapy with simultaneous lifestyle modification for the treatment of diabetic dyslipidemia [ ].
Many pharmacological therapies are currently available including statins, niacin, fatty acids of omega-3, sequestrants of bile acid, inhibitors of absorption of cholesterol, and fibrates [ ].
These drugs adopting different mechanisms of action have a crucial part in the treatment of diabetic dyslipidemia. The Collaborative Atorvastatin Diabetes Study CARDS study was carried out in T2 diabetes mellitus patients to evaluate the effect of statin therapy.
After 3. The CARDS study was stopped in between due to the significant results demonstrated in favor of statin therapy [ ]. After significant results of the CARDS study, the TNT trial was carried out, high dose versus low dose statin therapy in T2 DM patients to examine non-fatal MI, CAD mortality, and fatal non-fatal stroke risk.
After a follow-up period of 4. The HDL Atherosclerosis Treatment Study HATS trial is one of the first trials which examined the increased level of HDL cholesterol by niacin therapy and its effect on CV outcomes.
Patients with diabetes mellitus and CAN are at an elevated risk of cardiovascular associated mortality and morbidity as it is a very common complication of diabetes.
The autonomic dysfunction that occurs in diabetic patients is linked with an elevated risk of cardiac arrhythmia and sudden deaths. Other serious CV problems include myocardial ischemia, perioperative, and intraoperative CV instability, stroke, diabetic cardiomyopathy.
Common manifestations of CAN include hypotension, tachycardia, heart rate variability, and irregular blood pressure [ 73 ].
The complications and the pathogenesis of CAN can be reduced by the treatment of autonomic dysfunction [ 73 ]. According to many studies, it has been observed that strict glycemic control can be beneficial in reducing the occurrence of CAN in a diabetic patient.
An example of the mentioned statement is that reports by DCCT mentioning that patients measured for Hba1c and found to have enhanced glycemic control are safer and have a lower risk to develop autonomic dysfunction as measured by CAN index [ ].
Apart from glycemic control, many studies including the Steno-2 study states that by improving glucose control and cardiovascular risk factors, the incidence of CAN can be reduced in diabetic patients [ ]. Pharmacotherapy agents include angiotensin receptor blockers, ACE inhibitors, and aldose reductase inhibitors that help in decelerating the progression of cardiovascular autonomic neuropathy [ ].
The best pharmacological treatment is yet to be found by conducting various studies and researches. In cardiac myopathy, heart muscles become enlarged, thick, and rigid [ ].
The prevalence of cardiac myopathy also increases along with the severity of DM. Diabetic cardiomyopathy represents various conditions such as dysfunction of diastolic, remodeling dysfunctionally, and myocardial fibrosis [ 41 ].
Some treatment therapies are shown in Table 7 [ ]. Phytoconstituents also play a significant role in the treatment of various chronic diseases such as CVD, DM, and certain types of cancer.
Overproduction of oxygen free radicals in the human body and an increase in oxidative stress is involved in the pathogenesis of many chronic diseases. Chronic inflammation is also a significant factor that is involved in the pathogenesis of CVD and DM and cancers [ , , ].
So, the protective role of phytoconstituents is due to their antioxidant and anti-inflammatory properties. Phytoconstituents like curcumin, anthocyanins show anti-inflammatory properties by reducing the production of prostaglandins and by inhibiting nuclear factor к-B activity [ , ]. Obesity is one of the significant risk factors in CVD and DM could be treated by phytoconstituents.
Antioxidant defenses endogenous antioxidant activity is low in obese parts in comparison to their normal-weight counterparts [ ]. Fruits and plants which have a high saturation of antioxidant phytoconstituents show anti-obesity action.
Due to the high level of flavanones, citrus fruits show inhibitory activity on pancreatic lipase and α-glucosidase in vitro [ ]. Phytochemicals like proanthocyanidins and anthocyanins present in Aristotelia chilensis and Vaccinium floribundum limit the adipogenesis and inflammatory pathways in vitro [ ].
Antioxidant compounds including phenol carboxylic acids, ascorbic acid, flavonoids, iridoids which are present in Plantago maxima extract, could reverse diet-induced obesity. Grape products rich in polyphenols could reduce the obesity-mediated chronic inflammation through various mechanisms such as blocking proinflammatory cytokines, by activating transcription factors that antagonize chronic inflammation [ , ].
Resveratrol shows in vitro anti-obesity action by inhibiting adipogenesis. Curcumin also reduced obesity and related adverse effects of obesity. Allicin also showed anti-adipogenesis activities [ , ]. Apart from pharmacological interventions, complications of DM and CV disorders can be managed by modifications in the lifestyle.
Current treatment recommendations encourage obese DM patients to reduce their weight and in turn reduce risk factors for CVD.
The diabetes prevention program DPP and Finnish diabetes prevention data stated that lifestyle changes and weight loss prevents pre-diabetic patients from diabetes.
As in general, lifestyle interventions physical activity and diet leads to excess loss of VAT and ectopic fat which subsequently decreases CV risk profile [ , , ]. The lifestyle changes and management significantly assist in lowering blood pressure that is in controlling hypertension.
Other lifestyle changes needed to control hypertension includes increased physical activity, smoking cessation, and reducing sedentary time. Lifestyle changes have been found to show a role in lowering blood pressure enhances metabolism and vascular system and also plays a synergistic role with antihypertensive medications.
The treatment options or the ways to control and reduce the complications of the coexisting diseases with hypertension are lifestyle management, sodium reduction, physical activity, weight loss, sleep apnea treatment as shown in Table 8. For managing dyslipidemia, non-pharmacological therapy or lifestyle modifications consist of nutrition, physical exertion, and loss of weight.
Agents like peanuts, tree nuts, and grains should be consumed as they help in lowering cholesterol and blood pressure as they are a good source of unsaturated fat.
Weight loss improves blood pressure, reduces the level of triglycerides, and elevates HDL-C levels [ , , ]. Various investigations involving epidemiology have suggested that the effect of various T2DM linked loci can be reduced by upgrading lifestyle and dietary patterns.
The variant of PPARy that is Ala 12 is linked with enhancing the sensitivity of insulin. It has been found that the Ala 12 variant is more receptive to unsaturated fat than saturated fat. On the other hand, the Pro12 variant of PPARy shows more sensitivity to the damaging effects of malformed homeostasis of glucose and saturated fat.
There is evidence of a potential interaction between the TCF7L2 risk variant and lifestyle modifications such as MNT, physical activity, and dietary changes. The decline in insulin resistance and the reduced risk in the risk variant TCF7L2 can be attributed to lifestyle modification [ , , ].
There lies a shared SNP in obesity-linked genes such as FTO rs and fat mass. The SNP is linked with the increased vulnerability to T2DM. An increase in physical activity assists in reducing the FTO rsinduced obesity and the linked T2DM risk [ ]. The allele GCKRrs is an insulin raising allele, a result of SNP in glucokinase regulatory gene.
The gene interaction with whole grain reduces the carrier fasting insulin levels [ ]. The gene KCNQ1 belongs to the subfamily Q of potassium voltage-gated channel and is a susceptible gene to T2DM. Mutation in this gene results in a decline in insulin secretion.
The reduced expression of the Kcnq1 gene noncoding RNA Kcnq1ot1 region leads to an increment in Cdkn1c cyclin-dependent kinase inhibitor 1C expression that ultimately results in the decline of insulin release and cell mass of pancreatic-beta cells.
Reduction in hyperglycemia is also witnessed when there is an increment in the T2DM related genes SLC26A3, GABAAalpha1, SLC26A6, CIC, CFTR, and Bestrophin-3 expression due to the presence of Lactobacillus casei —a gut microbe [ ].
There is an urgent need to consider the possible interplay between multiple T2DM linked genes and lifestyle modifications as it can turn out to be an effective therapeutic intervention. There lies a direct correlation between diabetes management and diet and therefore medical nutrition therapy MNT serves as a complement to the traditional pharmacological intervention.
The American Diabetes Association ADA recommended personalized MNT to individuals who are diabetic or pre-diabetic for effective treatment by the registered dietician having proper knowledge of diabetes MNT [ ].
The combination of MNT and medical treatment has the potential for effective diabetes treatment. MNT can be defined as the nutritional diagnosis and treatment to manage a particular disease furnished by a nutritional professional or a registered dietician.
It also provides proper counseling service to the patient. The nutrition counseling of MNT provides a supportive process with priorities in order and to establish goals. It also involves the creation of individualized action plans to foster and acknowledge self-care [ ].
The effectiveness of MNT in the treatment of diabetes I and diabetes II has been demonstrated by research. In 18 studies reviewed by the American Dietetic Association in which the individuals were provided with the MNT by a registered dietician as a complement to the treatment demonstrated a positive effect of medical nutrition therapy on the management of diabetes by showing an improvement in the levels of A1C [ ].
It has been postulated by the ADA that MNT has potential in effective diabetes management whether type I or II. Several studies adapted from Pastors et al. in which MNT was included in the diabetes treatment intervention reported a 0. MNT has also successfully shown its role in preventing type 2 diabetes.
It has also been postulated that the type 2 diabetes onset can also be delayed with lifestyle modification such as changes in diet. The diabetes prevention program, , is a notable prevention study. The study was controlled and randomized. MNT shows a positive role in the management and prevention of type II diabetes in adults as shown in Table 9 but the same role of MNT is yet to be demonstrated for children and adolescents.
The study of the drug effects variation with the biological timing of the endogenous periods is known as chronopharmacology. The main aim behind chronopharmacology lies in understanding the predictable and periodic changes in both the desired and undesired effects of a drug.
Chronopharmacology may be divided into chronopharmacokinetics, chronotherapy, and chronotoxicity [ ]. Chronopharmacological aspects have shown to have an important role in the treatment and management of diabetes mellitus as the timing of medication and patient activities can have a major impact on the occurrence of troughs and peak in blood glucose levels [ ].
Changes in the biological clock are associated with increased rates of myocardial infarction. The misalignment in circadian cycles and behavioral cycle results in adversarial cardiometabolic endpoints such as increased arterial blood pressure, insulin, glucose, catecholamines, and cortisol [ ].
Circadian rhythm influences both the insulin release as well as the counterregulatory hormones such as glucagon, cortisol, growth hormone, and epinephrine that increase the blood glucose levels when needed. There is an increase in the level of growth hormone followed by a cortisol release surge and results in an overall elevated glucose production level by the liver in the middle of the night.
In people not suffering from diabetes, this increase in glucose is counteracted by the increased release of insulin in the pancreas and thus the glucose level remains constant. But, for people who suffer from type I diabetes and type II diabetes, the rise in blood glucose levels during sleep can have a significant effect on morning blood glucose levels.
Daily rhythmicity is exhibited by both the pancreatic insulin secretion and the target organs of insulin. This daily rhythmicity may be associated with glucose metabolism homeostasis maintenance for an effective treatment of diabetes.
It is necessary to correct these rhythms in diabetic patients. Several medications like glinides and long- and rapid-acting insulin analogs that are used to correct the impaired secretion of insulin have shown the chronotherapeutic approach. They are not only helpful in glycemic control but also reduce the risk of prolonged hypoglycemia and weight gain of the body.
Lifestyle modifications affect the biological clock of humans. A therapeutic agent is required for the correction of the impaired biological clock as it is challenging to alter lifestyles in modern societies [ , ]. While several studies led to the deeper comprehension of DM in the field of CVD, more work is needed to enhance the recognition and quantification of the threat of CV in DM patients.
Further investigation is required to decide how glycemic regulation correlates to CVD. Some research indicates that better glycemic regulation potentially improves CV results for DM patients [ 73 , ].
Researchers need further analysis to help to understand the connection among glycemic control and CVD growth, and to decide whether beginning and length of therapy are relevant in reducing events of CV in DM patients.
Additional studies are also required to figure out the best way of reducing cardiomyopathy and CAN risk and severity in DM patients. Several findings have also shown that autonomous dysfunction and cardiomyopathy of diabetes are disorder pathways that are normal in DM patients and raise the risk of potential CV problems.
Modifying lifestyle, greater regulation and active compounds seem to be of help in reducing CAN and cardiomyopathy of diabetes development [ , , , ]. Nevertheless, fewer researchers have analyzed the most appropriate possible treatment for these problems and what could be done to avoid the creation of such systems.
More work is required to better understand the regulation and management in people with diabetes of the typical risk factors of CVs, like blood pressure, obesity, and dyslipidemia. In comparison with the currently prescribed guidance based solely on statin prophylaxis, drug combination could be the best method of treating dyslipidemia.
Further studies such as IMPROVE-IT will help to decide what treatment is best for treating diabetic dyslipidemia [ ]. It also is uncertain if losing weight in patients with diabetes is appropriate for the clinically important enhancement of CV production as well as how much dieting is needed.
The related CVD could also be predicted to increase as the incidence of DM keeps growing, due to both the conventional factors of risk of DM and the direct impact on CVD. Further work to enhance knowledge of the disease state and its impact on CV function is required to boost medical treatment and CV results in people with diabetes.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R Global and regional diabetes prevalence estimates for and projections for and results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Diabetes Res Clin Pract Kharroubi AT Diabetes mellitus: the epidemic of the century. World J Diabetes Article PubMed PubMed Central Google Scholar. Bahia LR, Araujo DV, Schaan BD, Dib SA, Negrato CA, Leo MPS, Ramos AJS, Forti AC, Gomes MB, Foss MC, Monteiro RA, Sartorelli D, Franco LJ The costs of type 2 diabetes mellitus outpatient care in the Brazilian Public Health System.
Value Heal S—S Article Google Scholar. Yang W, Dall TM, Beronjia K, Lin J, Semilla AP, Chakrabarti R, Hogan PF, Petersen MP Economic costs of diabetes in the U. in Diabetes Care — Low Wang CC, Hess CN, Hiatt WR, Goldfine AB Clinical update: cardiovascular disease in diabetes mellitus.
Circulation — Article CAS PubMed PubMed Central Google Scholar. Centers for Disease Control and Prevention National Diabetes Statistics Report: estimates of diabetes and its burden in the United States. US Dep Heal Hum Serv , Report no: CS A. Russo GT, Baggio G, Rossi MC, Kautzky-Willer A Type 2 diabetes and cardiovascular risk in women.
Int J Endocrinol — Schmidt AM Diabetes mellitus and cardiovascular disease. Arterioscler Thromb Vasc Biol — Naser KA, Gruber A, Thomson GA The emerging pandemic of obesity and diabetes: are we doing enough to prevent a disaster?
Int J Clin Pract. Article CAS PubMed Google Scholar. Cercato C, Fonseca FA Cardiovascular risk and obesity. Diabetol Metab Syndr. Arner P, Rydén M Fatty acids, obesity and insulin resistance.
Obes Facts — Aguiar C, Duarte R, Carvalho D New approach to diabetes care: from blood glucose to cardiovascular disease. Rev Port Cardiol — Article PubMed Google Scholar.
Szekely Y, Arbel Y A review of interleukin-1 in heart disease: where do we stand today? Cardiol Ther — Leifheit-Nestler M, Wagner NM, Gogiraju R, Didié M, Konstantinides S, Hasenfuss G, Schäfer K Importance of leptin signaling and signal transducer and activator of transcription-3 activation in mediating the cardiac hypertrophy associated with obesity.
J Transl Med Luo JW, Zheng X, Cheng GC, Ye QH, Deng YZ, Wu L Resistin-induced cardiomyocyte hypertrophy is inhibited by apelin through the inactivation of extracellular signal-regulated kinase signaling pathway in H9c2 embryonic rat cardiomyocytes. Biomed Rep — Adiloğlu S, I, Yu C, Chen R, Li JJ, Li JJ, Drahansky M, Paridah M.
Intech i Mamo Y, Bekele F, Nigussie T, Zewudie A Determinants of poor glycemic control among adult patients with type 2 diabetes mellitus in Jimma University Medical Center, Jimma zone, south west Ethiopia: a case control study.
BMC Endocr Disord — Article CAS Google Scholar. Mezza T, Cinti F, Cefalo CMA, Pontecorvi A, Kulkarni RN, Giaccari A B-cell fate in human insulin resistance and type 2 diabetes: a perspective on islet plasticity.
Diabetes — Ragheb RM, Medhat A Mechanisms of fatty acid-induced insulin resistance in muscle and liver. Konigorski S, Janke J, Drogan D, Bergmann MM, Hierholzer J, Kaaks R, Boeing H, Pischon T Prediction of circulating adipokine levels based on body fat compartments and adipose tissue gene expression.
Shimobayashi M, Albert V, Woelnerhanssen B, Frei IC, Weissenberger D, Meyer-Gerspach AC, Clement N, Moes S, Colombi M, Meier JA, Swierczynska MM, Jenö P, Beglinger C, Peterli R, Hall MN Insulin resistance causes inflammation in adipose tissue.
J Clin Invest — Rasooly RS, Akolkar B, Spain LM, Guill MH, Del Vecchio CT, Carroll LE The national institute of diabetes and digestive and kidney diseases central repositories: a valuable resource for nephrology research.
Clin J Am Soc Nephrol — Shaikh A A practical approach to hypertension management in diabetes. Diabetes Ther. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.
Am J Cardiol — CHRISMED J Heal Res Group TDC and CTR The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med — Vogt L, Roelofs JJ Introduction to pathogenetic mechanisms of diabetic nephropathy. In: Diabetic Nephropathy. Springer International Publishing, Cham pp 83— Okada H, Watanabe Y, Kikuta T, Kobayashi T, Kanno Y, Sugaya T, Suzuki H Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade.
J Am Soc Nephrol — Cheung BMY Drug treatment for obesity in the post-sibutramine era. Drug Saf. Cheung BMY, Li C Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep. Qazi MU, Malik S Diabetes and cardiovascular disease: insights from the Framingham Heart Study.
Glob Heart — Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H Diabetes dyslipidemia. Abd-Allha E, Hassan B, Abduo M, Omar S, Sliem H Small dense low-density lipoprotein as a potential risk factor of nephropathy in type 2 diabetes mellitus.
Indian J Endocrinol Metab — De Ferranti SD, De Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK, Orchard TJ, Zinman B, Eckel RH Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.
Krauss RM Lipids and lipoproteins in patients with type 2 diabetes. Wu L, Parhofer KG Diabetic dyslipidemia. Ginsberg HN, Maccallum PR The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I.
Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. Sheth J, Shah A, Sheth F, Trivedi S, Nabar N, Shah N, Thakor P, Vaidya R The association of dyslipidemia and obesity with glycated hemoglobin.
Clin Diabetes Endocrinol Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E Long-term up to month efficacy and safety of concomitant prescription omegaacid ethyl esters and simvastatin in hypertriglyceridemic patients.
Curr Med Res Opin — J Diab Metab Disord Control — Jia G, Hill MA, Sowers JR Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity.
Negishi K Echocardiographic feature of diabetic cardiomyopathy: where are we now? Cardiovasc Diagn Ther. Santra S, Basu AK, Roychowdhury P, Banerjee R, Singhania P, Singh S, Datta UK Comparison of left ventricular mass in normotensive type 2 diabetes mellitus patients with that in the nondiabetic population.
J Cardiovasc Dis Res — Hall ME, Harmancey R, Stec DE Lean heart: role of leptin in cardiac hypertrophy and metabolism. World J Cardiol Lebeche D Diabetic cardiomyopathy: is resistin a culprit? Cardiovasc Diagn Ther — Patel S, Chauhan H, Amin G Diastolic dysfunction in asymptomatic type 2 diabetes mellitus OK tk.
NJIRM — Google Scholar. Bergerot C, Davidsen ES, Amaz C, Thibault H, Altman M, Bellaton A, Moulin P, Derumeaux G, Ernande L Diastolic function deterioration in type 2 diabetes mellitus: predictive factors over a 3-year follow-up.
Eur Heart J Cardiovasc Imaging — Tacito LHB, Pires AC, Yugar-Toledo JC Impaired flow-mediated dilation response and carotid intima-media thickness in patients with type 1 diabetes mellitus with a mean disease duration of 4.
Arch Endocrinol Metab — Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J — Gao Y, Ren Y, Guo YK, Liu X, Xie LJ, Jiang L, Shen MT, Deng MY, Yang ZG Metabolic syndrome and myocardium steatosis in subclinical type 2 diabetes mellitus: a 1H-magnetic resonance spectroscopy study.
Cardiovasc Diabetol McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ Screening for coronary artery disease in patients with diabetes.
In: Diabetes Care. American Diabetes Association, pp — Yu CM, Chau E, Sanderson JE, Fan K, Tang MO, Fung WH, Lin H, Kong SL, Lam YM, Hill MRS, Lau CP Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure.
Ng AC, Delgado V, Bertini M, Ewe SH, van der Meer RW, Rijzewijk LJ, Siebelink H-M, Smit JW, Diamant M, Romijn JA, de Roos A, Leung DY, Lamb HJ, Bax JJ Myocardial steatosis and left ventricular strain and strain rate imaging in patients with type 2 mellitus.
J Am Coll Cardiol A Ng ACT, Delgado V, Bertini M, Van Der Meer RW, Rijzewijk LJ, Hooi Ewe S, Siebelink HM, Smit JWA, Diamant M, Romijn JA, De Roos A, Leung DY, Lamb HJ, Bax JJ Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus.
Ringle A, Dornhorst A, Rehman MB, Ruisanchez C, Nihoyannopoulos P Evolution of subclinical myocardial dysfunction detected by two-dimensional and three-dimensional speckle tracking in asymptomatic type 1 diabetic patients: a long-term follow-up study. Echo Res Pract — Paolillo S, Rengo G, Pagano G, Pellegrino T, Savarese G, Femminella GD, Tuccillo M, Boemio A, Attena E, Formisano R, Petraglia L, Scopacasa F, Galasso G, Leosco D, Trimarco B, Cuocolo A, Perrone-Filardi P Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a I meta-iodobenzylguanidine I MIBG scintigraphic study.
Regan TJ, Lyons MM, Ahmed SS Evidence for cardiomyopathy in familial diabetes mellitus. Article PubMed Central Google Scholar. Tribouilloy C, Rusinaru D, Mahjoub H, Tartière JM, Kesri-Tartière L, Godard S, Peltier M Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study.
Heart — Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA Heart Failure with preserved ejection fraction in diabetes: mechanisms and management.
Can J Cardiol. Wilkinson MJ, Zadourian A, Taub PR Heart failure and diabetes mellitus: defining the problem and exploring the interrelationship. Am J Cardiol. Spallone V Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet.
Diabetes Metab. Moningi S, Nikhar S, Ramachandran G Autonomic disturbances in diabetes: assessment and anaesthetic implications. Indian J Anaesth. Agashe S, Petak S Cardiac autonomic neuropathy in diabetes mellitus. Methodist Debakey Cardiovasc. PubMed PubMed Central Google Scholar.
Fisher VL, Tahrani AA Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives. Diabetes, Metab. Targets Ther. CAS Google Scholar. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A Recent advances on the role of cytokines in atherosclerosis.
Vinik AI, Maser RE, Ziegler D Autonomic imbalance: prophet of doom or scope for hope? Diabet Med —
Diabetes and cardiovascular health disease affects your circulation too. And poor circulation makes hdalth diabetes Diabetes and cardiovascular health worse Diabetes and cardiovascular health like problems cardiovascilar your eyes and Insulin resistance and PCOS. If you cardovascular high blood sugar levels for Diabtees period of time, Duabetes slightly high, your blood vessels can start to get damaged and this can lead to serious heart complications. This is because your body can't use all of this sugar properly, so more of it sticks to your red blood cells and builds up in your blood. This build-up can block and damage the vessels carrying blood to and from your heart, starving the heart of oxygen and nutrients.
DEAR MAYO Cardiovasvular Energy-boosting plant oils Diahetes 42 and recently was diagnosed Diabetes and cardiovascular health diabetes. My doctor Increase energy levels slimming pills I could manage the condition with cardiovacsular and exercise caridovascular now but suggested I Diabetes and cardiovascular health up with a cardiovascualr. As far as I know, my heart is fine. What is the connection between diabetes and heart health? ANSWER: The number of people worldwide with diabetes is rising. While many may not realize it, having diabetes comes with a higher risk for heart disease. Research has shown that people with Type 2 diabetes are up to four times more likely than the general population to die from cardiovascular causes.
0 thoughts on “Diabetes and cardiovascular health”